Chromocell TherapeuticsCHRO
Market Cap: $5.18M
About: Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
Employees: 7
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
400% more funds holding
Funds holding: 1 [Q1] → 5 (+4) [Q2]
1.25% less ownership
Funds ownership: 5.06% [Q1] → 3.81% (-1.25%) [Q2]
56% less capital invested
Capital invested by funds: $660K [Q1] → $290K (-$370K) [Q2]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for CHRO.